{"transactions":[{"id":4628448,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-03T01:29:27.000Z","date":"2026-10-01","kind":"exercise","planned":true,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter\nof which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's\ncontinued employment with the Issuer."}],"balance_after":312357,"derivative":{"exercise_price":14.5,"expiration_date":"2033-09-01","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001636282-26-000117","document":"wk-form4_1790990964.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000117/wk-form4_1790990964.xml","form_type":"4"}},{"id":4628447,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-03T01:29:27.000Z","date":"2026-09-30","kind":"exercise","planned":true,"acquired":false,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter\nof which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's\ncontinued employment with the Issuer."}],"balance_after":319857,"derivative":{"exercise_price":14.5,"expiration_date":"2033-09-01","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001636282-26-000117","document":"wk-form4_1790990964.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000117/wk-form4_1790990964.xml","form_type":"4"}},{"id":4628446,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-03T01:29:27.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":229,"price":93.57,"value":21427.53,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.54 to $93.59, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"Includes 33,738 RSUs. Each RSU represents a contingent right to receive, upon vesting, one share of the Issuer's common stock. The RSUs vest on September 1, 2027, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":79762,"source":{"system":"sec-edgar","filing":"0001636282-26-000117","document":"wk-form4_1790990964.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000117/wk-form4_1790990964.xml","form_type":"4"}},{"id":4628445,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-03T01:29:27.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":3071,"price":92.95,"value":285449.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.54 to $93.53, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":79991,"source":{"system":"sec-edgar","filing":"0001636282-26-000117","document":"wk-form4_1790990964.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000117/wk-form4_1790990964.xml","form_type":"4"}},{"id":4628444,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-03T01:29:27.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":2100,"price":91.92,"value":193032.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.41 to $92.26, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":83062,"source":{"system":"sec-edgar","filing":"0001636282-26-000117","document":"wk-form4_1790990964.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000117/wk-form4_1790990964.xml","form_type":"4"}},{"id":4628443,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-03T01:29:27.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":90.27,"value":135405.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.96 to $90.95, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":85162,"source":{"system":"sec-edgar","filing":"0001636282-26-000117","document":"wk-form4_1790990964.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000117/wk-form4_1790990964.xml","form_type":"4"}},{"id":4628442,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-03T01:29:27.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":600,"price":89.07,"value":53442.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.53, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."}],"balance_after":86662,"source":{"system":"sec-edgar","filing":"0001636282-26-000117","document":"wk-form4_1790990964.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000117/wk-form4_1790990964.xml","form_type":"4"}},{"id":4628441,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-03T01:29:27.000Z","date":"2026-10-01","kind":"exercise","planned":true,"acquired":true,"shares":7500,"price":14.5,"value":108750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."}],"balance_after":87262,"source":{"system":"sec-edgar","filing":"0001636282-26-000117","document":"wk-form4_1790990964.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000117/wk-form4_1790990964.xml","form_type":"4"}},{"id":4628440,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-03T01:29:27.000Z","date":"2026-09-30","kind":"sale","planned":true,"acquired":false,"shares":17500,"price":89.89,"value":1573075.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.00 to $90.62, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."}],"balance_after":79762,"source":{"system":"sec-edgar","filing":"0001636282-26-000117","document":"wk-form4_1790990964.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000117/wk-form4_1790990964.xml","form_type":"4"}},{"id":4628439,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-03T01:29:27.000Z","date":"2026-09-30","kind":"exercise","planned":true,"acquired":true,"shares":17500,"price":14.5,"value":253750.0,"ownership":{"direct":true},"balance_after":97262,"source":{"system":"sec-edgar","filing":"0001636282-26-000117","document":"wk-form4_1790990964.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000117/wk-form4_1790990964.xml","form_type":"4"}},{"id":4037,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-04T01:33:44.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter\nof which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's\ncontinued employment with the Issuer."}],"balance_after":337357,"derivative":{"exercise_price":14.5,"expiration_date":"2033-09-01","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001636282-26-000109","document":"wk-form4_1788485622.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000109/wk-form4_1788485622.xml","form_type":"4"}},{"id":4036,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-04T01:33:44.000Z","date":"2026-09-02","kind":"sale","planned":true,"acquired":false,"shares":18232,"price":89.35,"value":1629029.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"The transaction reported reflects the sale of shares of the Issuer's common stock in satisfaction of the Reporting Person's tax liability in connection with the settlement of 33,738 restricted stock units (\"RSUs\"). This sale was made to satisfy tax withholding obligations through a \"sell to cover\" transaction and does not represent a discretionary trade made by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Includes 33,738 RSUs. Each RSU represents a contingent right to receive, upon vesting, one share of the Issuer's common stock. The RSUs vest on September 1, 2027, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":79762,"source":{"system":"sec-edgar","filing":"0001636282-26-000109","document":"wk-form4_1788485622.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000109/wk-form4_1788485622.xml","form_type":"4"}},{"id":4035,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-04T01:33:44.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":200,"price":89.04,"value":17808.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.69 to $89.38, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price\nwithin the range."}],"balance_after":97994,"source":{"system":"sec-edgar","filing":"0001636282-26-000109","document":"wk-form4_1788485622.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000109/wk-form4_1788485622.xml","form_type":"4"}},{"id":4034,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-04T01:33:44.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":2016,"price":88.03,"value":177468.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.64 to $88.59, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price\nwithin the range."}],"balance_after":98194,"source":{"system":"sec-edgar","filing":"0001636282-26-000109","document":"wk-form4_1788485622.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000109/wk-form4_1788485622.xml","form_type":"4"}},{"id":4033,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-04T01:33:44.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":4384,"price":87.11,"value":381890.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.60 to $87.57, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price\nwithin the range."}],"balance_after":100210,"source":{"system":"sec-edgar","filing":"0001636282-26-000109","document":"wk-form4_1788485622.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000109/wk-form4_1788485622.xml","form_type":"4"}},{"id":4032,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-04T01:33:44.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":900,"price":86.25,"value":77625.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.60 to $86.53, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."}],"balance_after":104594,"source":{"system":"sec-edgar","filing":"0001636282-26-000109","document":"wk-form4_1788485622.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000109/wk-form4_1788485622.xml","form_type":"4"}},{"id":4031,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-04T01:33:44.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":true,"shares":7500,"price":14.5,"value":108750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."}],"balance_after":105494,"source":{"system":"sec-edgar","filing":"0001636282-26-000109","document":"wk-form4_1788485622.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000109/wk-form4_1788485622.xml","form_type":"4"}},{"id":695864,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-06T01:32:04.000Z","date":"2026-08-03","kind":"exercise","planned":true,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter\nof which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's\ncontinued employment with the Issuer."}],"balance_after":344857,"derivative":{"exercise_price":14.5,"expiration_date":"2033-09-01","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001636282-26-000100","document":"wk-form4_1785979922.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000100/wk-form4_1785979922.xml","form_type":"4"}},{"id":695863,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-06T01:32:04.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":100,"price":97.1,"value":9710.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 67,476 restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of\nSeptember 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":97994,"source":{"system":"sec-edgar","filing":"0001636282-26-000100","document":"wk-form4_1785979922.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000100/wk-form4_1785979922.xml","form_type":"4"}},{"id":695862,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-06T01:32:04.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":2300,"price":96.3,"value":221490.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $95.85 to $96.82, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":98094,"source":{"system":"sec-edgar","filing":"0001636282-26-000100","document":"wk-form4_1785979922.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000100/wk-form4_1785979922.xml","form_type":"4"}},{"id":695861,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-06T01:32:04.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":5100,"price":95.21,"value":485571.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $94.84 to $95.83, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."}],"balance_after":100394,"source":{"system":"sec-edgar","filing":"0001636282-26-000100","document":"wk-form4_1785979922.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000100/wk-form4_1785979922.xml","form_type":"4"}},{"id":695860,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-06T01:32:04.000Z","date":"2026-08-03","kind":"exercise","planned":true,"acquired":true,"shares":7500,"price":14.5,"value":108750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."}],"balance_after":105494,"source":{"system":"sec-edgar","filing":"0001636282-26-000100","document":"wk-form4_1785979922.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000100/wk-form4_1785979922.xml","form_type":"4"}},{"id":718268,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-03T01:33:59.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter\nof which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's\ncontinued employment with the Issuer."}],"balance_after":352357,"derivative":{"exercise_price":14.5,"expiration_date":"2033-09-01","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001636282-26-000088","document":"wk-form4_1783042436.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000088/wk-form4_1783042436.xml","form_type":"4"}},{"id":718267,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-03T01:33:59.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":1725,"price":88.37,"value":152438.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.17 to $89.01, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 67,476 restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":97994,"source":{"system":"sec-edgar","filing":"0001636282-26-000088","document":"wk-form4_1783042436.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000088/wk-form4_1783042436.xml","form_type":"4"}},{"id":718266,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-03T01:33:59.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":5775,"price":87.55,"value":505601.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.13 to $88.05, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."}],"balance_after":99719,"source":{"system":"sec-edgar","filing":"0001636282-26-000088","document":"wk-form4_1783042436.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000088/wk-form4_1783042436.xml","form_type":"4"}},{"id":718265,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-03T01:33:59.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":true,"shares":7500,"price":14.5,"value":108750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."}],"balance_after":105494,"source":{"system":"sec-edgar","filing":"0001636282-26-000088","document":"wk-form4_1783042436.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000088/wk-form4_1783042436.xml","form_type":"4"}},{"id":725608,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-27T01:31:44.000Z","date":"2026-06-25","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter\nof which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's\ncontinued employment with the Issuer."}],"balance_after":359857,"derivative":{"exercise_price":14.5,"expiration_date":"2033-09-01","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001853327-26-000008","document":"wk-form4_1782523902.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000185332726000008/wk-form4_1782523902.xml","form_type":"4"}},{"id":725607,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-27T01:31:44.000Z","date":"2026-06-25","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":87.14,"value":871400.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.78 to $87.43, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 67,476 restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":97994,"source":{"system":"sec-edgar","filing":"0001853327-26-000008","document":"wk-form4_1782523902.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000185332726000008/wk-form4_1782523902.xml","form_type":"4"}},{"id":725606,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-27T01:31:44.000Z","date":"2026-06-25","kind":"sale","planned":false,"acquired":false,"shares":5000,"price":87.12,"value":435600.0,"ownership":{"direct":true},"balance_after":107994,"source":{"system":"sec-edgar","filing":"0001853327-26-000008","document":"wk-form4_1782523902.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000185332726000008/wk-form4_1782523902.xml","form_type":"4"}},{"id":725605,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-27T01:31:44.000Z","date":"2026-06-25","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":14.5,"value":217500.0,"ownership":{"direct":true},"balance_after":112994,"source":{"system":"sec-edgar","filing":"0001853327-26-000008","document":"wk-form4_1782523902.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000185332726000008/wk-form4_1782523902.xml","form_type":"4"}},{"id":752003,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-04T01:30:41.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":374857,"derivative":{"exercise_price":14.5,"expiration_date":"2033-09-01","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001636282-26-000076","document":"wk-form4_1780536638.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000076/wk-form4_1780536638.xml","form_type":"4"}},{"id":752002,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-04T01:30:41.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":3100,"price":72.06,"value":223386.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.54 to $72.14, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 67,476 restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":97994,"source":{"system":"sec-edgar","filing":"0001636282-26-000076","document":"wk-form4_1780536638.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000076/wk-form4_1780536638.xml","form_type":"4"}},{"id":752001,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-04T01:30:41.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":2599,"price":70.77,"value":183931.23,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.38 to $71.34, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":101094,"source":{"system":"sec-edgar","filing":"0001636282-26-000076","document":"wk-form4_1780536638.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000076/wk-form4_1780536638.xml","form_type":"4"}},{"id":752000,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-04T01:30:41.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":1801,"price":69.75,"value":125619.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.37 to $70.36, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."}],"balance_after":103693,"source":{"system":"sec-edgar","filing":"0001636282-26-000076","document":"wk-form4_1780536638.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000076/wk-form4_1780536638.xml","form_type":"4"}},{"id":751999,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-04T01:30:41.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":true,"shares":7500,"price":14.5,"value":108750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."}],"balance_after":105494,"source":{"system":"sec-edgar","filing":"0001636282-26-000076","document":"wk-form4_1780536638.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000076/wk-form4_1780536638.xml","form_type":"4"}},{"id":795809,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-02T01:35:12.000Z","date":"2026-05-01","kind":"exercise","planned":true,"acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":382357,"derivative":{"exercise_price":14.5,"expiration_date":"2033-09-01","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001853327-26-000005","document":"wk-form4_1777685708.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000185332726000005/wk-form4_1777685708.xml","form_type":"4"}},{"id":795808,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-02T01:35:12.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":12500,"price":71.37,"value":892125.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 67,476 restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":97994,"source":{"system":"sec-edgar","filing":"0001853327-26-000005","document":"wk-form4_1777685708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000185332726000005/wk-form4_1777685708.xml","form_type":"4"}},{"id":795807,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-02T01:35:12.000Z","date":"2026-05-01","kind":"exercise","planned":true,"acquired":true,"shares":12500,"price":14.5,"value":181250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."}],"balance_after":110494,"source":{"system":"sec-edgar","filing":"0001853327-26-000005","document":"wk-form4_1777685708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000185332726000005/wk-form4_1777685708.xml","form_type":"4"}},{"id":816735,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-04T01:29:36.000Z","date":"2026-04-01","kind":"exercise","planned":true,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":394857,"derivative":{"exercise_price":14.5,"expiration_date":"2033-09-01","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001853327-26-000003","document":"wk-form4_1775266173.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000185332726000003/wk-form4_1775266173.xml","form_type":"4"}},{"id":816734,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-04T01:29:36.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":1300,"price":49.98,"value":64974.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.76 to $50.15, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 67,476 restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":97994,"source":{"system":"sec-edgar","filing":"0001853327-26-000003","document":"wk-form4_1775266173.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000185332726000003/wk-form4_1775266173.xml","form_type":"4"}},{"id":816733,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-04T01:29:36.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":6200,"price":49.21,"value":305102.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.69 to $49.63, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."}],"balance_after":99294,"source":{"system":"sec-edgar","filing":"0001853327-26-000003","document":"wk-form4_1775266173.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000185332726000003/wk-form4_1775266173.xml","form_type":"4"}},{"id":816732,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-04T01:29:36.000Z","date":"2026-04-01","kind":"exercise","planned":true,"acquired":true,"shares":7500,"price":14.5,"value":108750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."}],"balance_after":105494,"source":{"system":"sec-edgar","filing":"0001853327-26-000003","document":"wk-form4_1775266173.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000185332726000003/wk-form4_1775266173.xml","form_type":"4"}},{"id":868096,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-04T02:32:31.000Z","date":"2026-03-03","kind":"exercise","planned":true,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":402357,"derivative":{"exercise_price":14.5,"expiration_date":"2033-09-01","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001636282-26-000028","document":"wk-form4_1772591549.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000028/wk-form4_1772591549.xml","form_type":"4"}},{"id":868095,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-04T02:32:31.000Z","date":"2026-03-03","kind":"sale","planned":true,"acquired":false,"shares":200,"price":41.66,"value":8332.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.55 to $41.76, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 67,476 restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":97994,"source":{"system":"sec-edgar","filing":"0001636282-26-000028","document":"wk-form4_1772591549.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000028/wk-form4_1772591549.xml","form_type":"4"}},{"id":868094,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-04T02:32:31.000Z","date":"2026-03-03","kind":"sale","planned":true,"acquired":false,"shares":2300,"price":40.56,"value":93288.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.17 to $41.11, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."}],"balance_after":98194,"source":{"system":"sec-edgar","filing":"0001636282-26-000028","document":"wk-form4_1772591549.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000028/wk-form4_1772591549.xml","form_type":"4"}},{"id":868093,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-04T02:32:31.000Z","date":"2026-03-03","kind":"exercise","planned":true,"acquired":true,"shares":2500,"price":14.5,"value":36250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."}],"balance_after":100494,"source":{"system":"sec-edgar","filing":"0001636282-26-000028","document":"wk-form4_1772591549.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000028/wk-form4_1772591549.xml","form_type":"4"}},{"id":940138,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-14T02:27:45.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 140,000 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date."}],"balance_after":140000,"derivative":{"exercise_price":30.61,"expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001636282-26-000004","document":"wk-form4_1768357662.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000004/wk-form4_1768357662.xml","form_type":"4"}},{"id":1049931,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-09-03T22:53:19.000Z","date":"2025-09-02","kind":"sale","planned":false,"acquired":false,"shares":18428,"price":16.26,"value":299639.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction reported reflects the sale of shares of common stock, par value $0.0001 per share, of the Issuer (\"Common Stock\") in satisfaction of the Reporting Person's tax liability in connection with the settlement of 33,738 restricted stock units (\"RSUs\"). This sale was made to satisfy tax withholding obligations through a \"sell to cover\" transaction and does not represent a discretionary trade made by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average sale price of the Common Stock. These shares were sold in multiple transactions at prices ranging from $16.26 to $16.30, inclusive. The Reporting Person undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 67,476 RSUs. Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":97994,"source":{"system":"sec-edgar","filing":"0001636282-25-000095","document":"wk-form4_1756939995.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628225000095/wk-form4_1756939995.xml","form_type":"4"}},{"id":1300225,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-17T21:36:48.000Z","date":"2025-01-15","kind":"grant","planned":false,"acquired":true,"shares":95500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 95,500 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date."}],"balance_after":95500,"derivative":{"exercise_price":21.66,"expiration_date":"2035-01-15","underlying":"Common Stock","underlying_shares":95500},"source":{"system":"sec-edgar","filing":"0001636282-25-000010","document":"wk-form4_1737149801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628225000010/wk-form4_1737149801.xml","form_type":"4"}},{"id":1414108,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-09-05T20:04:14.000Z","date":"2024-09-03","kind":"sale","planned":false,"acquired":false,"shares":18531,"price":28.173,"value":522073.863,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction reported reflects the sale of shares of common stock, par value $0.0001 per share, of the Issuer (\"Common Stock\") in satisfaction of the Reporting Person's tax liability in connection with the settlement of 33,739 restricted stock units (\"RSUs\"). This sale was made to satisfy tax withholding obligations through a \"sell to cover\" transaction and does not represent a discretionary trade made by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average sale price of the Common Stock. These shares were sold in multiple transactions at prices ranging from $27.72 to $28.18, inclusive. The Reporting Person undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 101,214 RSUs. Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in three equal installments on each of September 1, 2025, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":116422,"source":{"system":"sec-edgar","filing":"0001636282-24-000062","document":"wk-form4_1725566647.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628224000062/wk-form4_1725566647.xml","form_type":"4"}},{"id":1662059,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-03T01:27:03.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option a right to purchase 70,000 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date."}],"balance_after":70000,"derivative":{"exercise_price":25.86,"expiration_date":"2034-02-01","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0000950170-24-010901","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000095017024010901/ownership.xml","form_type":"4"}},{"id":1701031,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-12-22T23:00:19.000Z","date":"2023-12-22","kind":"grant","planned":false,"acquired":true,"shares":134953,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 134,953 restricted stock units (\"RSUs\") granted under the Spyre Therapeutics, Inc. 2016 Equity Incentive Plan, as Amended and Restated. Each RSU represents a contingent right to receive, upon vesting, one share of common stock, par value $0.0001 per share, of the Issuer. The RSUs vest as to one-fourth on each anniversary of September 1, 2023, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":134953,"source":{"system":"sec-edgar","filing":"0000950170-23-072763","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000095017023072763/ownership.xml","form_type":"4"}},{"id":1789390,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-05T20:10:16.000Z","date":"2023-09-01","kind":"grant","planned":false,"acquired":true,"shares":10121441,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 10,121,441 shares of the Issuer's common stock, one quarter of which will vest and become exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":10121441,"derivative":{"exercise_price":0.58,"expiration_date":"2033-09-01","underlying":"Common Stock","underlying_shares":10121441},"source":{"system":"sec-edgar","filing":"0000950170-23-046384","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000095017023046384/ownership.xml","form_type":"4"}},{"id":1963511,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-08T21:29:15.000Z","date":"2023-03-06","kind":"sale","acquired":false,"shares":291,"price":15.2634,"value":4441.6494,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $15.120 to $15.440, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":59115,"source":{"system":"sec-edgar","filing":"0001567619-23-004671","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000156761923004671/doc1.xml","form_type":"4"}},{"id":1969381,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-06T23:58:30.000Z","date":"2023-03-02","kind":"grant","acquired":true,"shares":55800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from March 2, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":55800,"derivative":{"exercise_price":15.82,"expiration_date":"2033-03-02","underlying":"Common Stock","underlying_shares":55800},"source":{"system":"sec-edgar","filing":"0001567619-23-004547","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000156761923004547/doc1.xml","form_type":"4"}},{"id":1969380,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-06T23:58:30.000Z","date":"2023-03-02","kind":"grant","acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on March 2 of each year, beginning March 2, 2024, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":59406,"source":{"system":"sec-edgar","filing":"0001567619-23-004547","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000156761923004547/doc1.xml","form_type":"4"}},{"id":1979958,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-03T00:05:53.000Z","date":"2023-03-02","kind":"sale","acquired":false,"shares":18,"price":16.52,"value":297.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":38406,"source":{"system":"sec-edgar","filing":"0001567619-23-004270","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000156761923004270/doc1.xml","form_type":"4"}},{"id":1979957,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-03T00:05:53.000Z","date":"2023-03-02","kind":"sale","acquired":false,"shares":1416,"price":15.8183,"value":22398.7128,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades in prices ranging from $15.470 to $16.460, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":38424,"source":{"system":"sec-edgar","filing":"0001567619-23-004270","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000156761923004270/doc1.xml","form_type":"4"}},{"id":1979956,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-03T00:05:53.000Z","date":"2023-02-28","kind":"sale","acquired":false,"shares":416,"price":16.1663,"value":6725.1808,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $15.990 to $16.320, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":39840,"source":{"system":"sec-edgar","filing":"0001567619-23-004270","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000156761923004270/doc1.xml","form_type":"4"}},{"id":2154168,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-09-20T20:37:22.000Z","date":"2022-09-16","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vest on the one year anniversary measured from May 22, 2019 (the \"Vesting Commencement Date\") and 1/48th of the shares vest on each monthly anniversary thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":37277,"derivative":{"exercise_price":1.6806,"expiration_date":"2029-06-11","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001567619-22-017633","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000156761922017633/doc1.xml","form_type":"4"}},{"id":2154167,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-09-20T20:37:22.000Z","date":"2022-09-16","kind":"exercise","acquired":true,"shares":5000,"price":1.6806,"value":8403.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 17,400 restricted stock units."}],"balance_after":40256,"source":{"system":"sec-edgar","filing":"0001567619-22-017633","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000156761922017633/doc1.xml","form_type":"4"}},{"id":2348236,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-08T01:49:16.000Z","date":"2022-03-03","kind":"grant","acquired":true,"shares":35300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from March 3, 2022 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":35300,"derivative":{"exercise_price":17.67,"expiration_date":"2032-03-03","underlying":"Common Stock","underlying_shares":35300},"source":{"system":"sec-edgar","filing":"0001567619-22-006494","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000156761922006494/doc1.xml","form_type":"4"}},{"id":2348235,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-08T01:49:16.000Z","date":"2022-03-07","kind":"sale","acquired":false,"shares":10,"price":16.4449,"value":164.449,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction was executed in multiple trades in prices ranging from $16.44 to $16.45, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 17,400 RSUs."}],"balance_after":35256,"source":{"system":"sec-edgar","filing":"0001567619-22-006494","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000156761922006494/doc1.xml","form_type":"4"}},{"id":2348234,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-08T01:49:16.000Z","date":"2022-03-04","kind":"sale","acquired":false,"shares":293,"price":16.8591,"value":4939.7163,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades in prices ranging from $16.63 to $17.19, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":35266,"source":{"system":"sec-edgar","filing":"0001567619-22-006494","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000156761922006494/doc1.xml","form_type":"4"}},{"id":2348233,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-08T01:49:16.000Z","date":"2022-03-03","kind":"grant","acquired":true,"shares":13300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on March 3 of each year, beginning March 3, 2023, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":35559,"source":{"system":"sec-edgar","filing":"0001567619-22-006494","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000156761922006494/doc1.xml","form_type":"4"}},{"id":2355277,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-03T21:17:19.000Z","date":"2022-03-01","kind":"sale","acquired":false,"shares":420,"price":17.7527,"value":7456.134,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units (\"RSUs\"). Shares and RSUs remain subject to a lock-up agreement with the underwriters for the Issuer's follow-on offering in February 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $17.40 to $18.185, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 4,800 Restricted Stock Units (\"RSUs\"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof."}],"balance_after":22259,"source":{"system":"sec-edgar","filing":"0001567619-22-006228","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000156761922006228/doc1.xml","form_type":"4"}},{"id":2449948,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-05T02:05:03.000Z","date":"2021-12-30","kind":"grant","acquired":true,"shares":55704,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On August 24, 2021, the Reporting Person was granted the option subject to a milestone condition. The Compensation Committee of the Issuer certified the achievement of the milestone and commencement of vesting on December 30, 2021 (the \"Milestone Vesting Commencement Date\"). 1/48th of the shares subject to the option shall vest on each monthly anniversary of the Milestone Vesting Commencement Date, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Milestone Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":55704,"derivative":{"exercise_price":20.59,"expiration_date":"2031-08-23","underlying":"Common Stock","underlying_shares":55704},"source":{"system":"sec-edgar","filing":"0001567619-22-000388","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000156761922000388/doc1.xml","form_type":"4"}},{"id":2457969,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-28T22:00:12.000Z","date":"2021-12-27","kind":"sale","acquired":false,"shares":12560,"price":20.0748,"value":252139.488,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades in prices ranging from $19.88 to $20.31, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,800 Restricted Stock Units (\"RSUs\"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof."}],"balance_after":22679,"source":{"system":"sec-edgar","filing":"0000899243-21-049940","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000089924321049940/doc4.xml","form_type":"4"}},{"id":2758336,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-05T22:50:12.000Z","date":"2021-04-01","kind":"grant","acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from April 1, 2021 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":23000,"derivative":{"exercise_price":29.74,"expiration_date":"2031-04-01","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001567619-21-007651","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000156761921007651/doc1.xml","form_type":"4"}}]}